AIM: To characterize longitudinally the inflammation and the gut microbiota dynamics in a mouse model of dextran sulfate sodium (DSS)-induced colitis. METHODS: In animal models, the most common method used to trigger colitis is based on the oral administration of the sulfated polysaccharides DSS. The murine DSS colitis model has been widely adopted to induce severe acute, chronic or semi-chronic colitis, and has been validated as an important model for the translation of mice data to human inflammatory bowel disease (IBD). However, it is now clear that models characterized by mild intestinal damage are more accurate for studying the effects of therapeutic agents. For this reason, we have developed a murine model of mild colitis to study longitudinally the inflammation and microbiota dynamics during the intestinal repair processes, and to obtain data suitable to support the recovery of gut microbiota-host homeostasis. RESULTS: All plasma cytokines evaluated, except IL-17, began to increase (P < 0.05), after 7 d of DSS administration. IL-17 only began to increase 4 d after DSS withdrawal. IL-1β and IL-17 continue to increase during the recovery phase, even when clinical signs of colitis had disappeared. IL-6, IL-10 and IFN-γ reached their maxima 4 d after DSS withdrawal and decreased during the late recovery phase. TNFα reached a peak (a three- fold increase, P < 0.05), after which it slightly decreased, only to increase again close to the end of the recovery phase. DSS administration induced profound and rapid changes in the mice gut microbiota. After 3 d of DSS administration, we observed a major reduction in Bacteroidetes/Prevotella and a corresponding increase in Bacillaceae, with respect to control mice. In particular, Bacteroidetes/Prevotella decreased from a relative abundance of 59.42%-33.05%, while Bacillaceae showed a concomitant increase from 2.77% to 10.52%. Gut microbiota rapidly shifted toward a healthy profile during the recovery phase and returned normal 4 d after DSS withdrawal. Cyclooxygenase 2 expression started to increase 4 d after DSS withdrawal (P < 0.05), when dysbiosis had recovered, and continued to increase during the recovery phase. Taken together, these data indicated that a chronic phase of intestinal inflammation, characterized by the absence of dysbiosis, could be obtained in mice using a single DSS cycle. CONCLUSION: Dysbiosis contributes to the local and systemic inflammation that occurs in the DSS model of colitis; however, chronic bowel inflammation is maintained even after recovery from dysbiosis.
AIM: To characterize longitudinally the inflammation and the gut microbiota dynamics in a mouse model of dextran sulfate sodium (DSS)-induced colitis. METHODS: In animal models, the most common method used to trigger colitis is based on the oral administration of the sulfated polysaccharidesDSS. The murineDSScolitis model has been widely adopted to induce severe acute, chronic or semi-chronic colitis, and has been validated as an important model for the translation of mice data to humaninflammatory bowel disease (IBD). However, it is now clear that models characterized by mild intestinal damage are more accurate for studying the effects of therapeutic agents. For this reason, we have developed a murine model of mild colitis to study longitudinally the inflammation and microbiota dynamics during the intestinal repair processes, and to obtain data suitable to support the recovery of gut microbiota-host homeostasis. RESULTS: All plasma cytokines evaluated, except IL-17, began to increase (P < 0.05), after 7 d of DSS administration. IL-17 only began to increase 4 d after DSS withdrawal. IL-1β and IL-17 continue to increase during the recovery phase, even when clinical signs of colitis had disappeared. IL-6, IL-10 and IFN-γ reached their maxima 4 d after DSS withdrawal and decreased during the late recovery phase. TNFα reached a peak (a three- fold increase, P < 0.05), after which it slightly decreased, only to increase again close to the end of the recovery phase. DSS administration induced profound and rapid changes in the mice gut microbiota. After 3 d of DSS administration, we observed a major reduction in Bacteroidetes/Prevotella and a corresponding increase in Bacillaceae, with respect to control mice. In particular, Bacteroidetes/Prevotella decreased from a relative abundance of 59.42%-33.05%, while Bacillaceae showed a concomitant increase from 2.77% to 10.52%. Gut microbiota rapidly shifted toward a healthy profile during the recovery phase and returned normal 4 d after DSS withdrawal. Cyclooxygenase 2 expression started to increase 4 d after DSS withdrawal (P < 0.05), when dysbiosis had recovered, and continued to increase during the recovery phase. Taken together, these data indicated that a chronic phase of intestinal inflammation, characterized by the absence of dysbiosis, could be obtained in mice using a single DSS cycle. CONCLUSION:Dysbiosis contributes to the local and systemic inflammation that occurs in the DSS model of colitis; however, chronic bowel inflammation is maintained even after recovery from dysbiosis.
Authors: Ashis K Samanta; Valeria A Torok; Nigel J Percy; Suzanne M Abimosleh; Gordon S Howarth Journal: J Microbiol Date: 2012-04-27 Impact factor: 3.422
Authors: Hamed Laroui; Sarah A Ingersoll; Hong Chun Liu; Mark T Baker; Saravanan Ayyadurai; Moiz A Charania; Famina Laroui; Yutao Yan; Shanthi V Sitaraman; Didier Merlin Journal: PLoS One Date: 2012-03-09 Impact factor: 3.240
Authors: Lori A Coburn; Xue Gong; Kshipra Singh; Mohammad Asim; Brooks P Scull; Margaret M Allaman; Christopher S Williams; Michael J Rosen; M Kay Washington; Daniel P Barry; M Blanca Piazuelo; Robert A Casero; Rupesh Chaturvedi; Zhongming Zhao; Keith T Wilson Journal: PLoS One Date: 2012-03-12 Impact factor: 3.240
Authors: Enzo Spisni; Maria C Valerii; Luigia De Fazio; Elena Cavazza; Francesca Borsetti; Annamaria Sgromo; Marco Candela; Manuela Centanni; Fernando Rizello; Antonio Strillacci Journal: Mol Ther Date: 2014-11-13 Impact factor: 11.454
Authors: Paola Menghini; Daniele Corridoni; Ludovica F Buttó; Abdullah Osme; Sushma Shivaswamy; Minh Lam; Giorgos Bamias; Theresa T Pizarro; Alexander Rodriguez-Palacios; Charles A Dinarello; Fabio Cominelli Journal: Proc Natl Acad Sci U S A Date: 2019-12-16 Impact factor: 11.205
Authors: Katja M Bendtsen; Camilla Hf Hansen; Lukasz Krych; Karsten Buschard; Helene Farlov; Axel K Hansen Journal: Comp Med Date: 2017-10-01 Impact factor: 0.982
Authors: Lien Van den Bossche; Pieter Hindryckx; Lindsey Devisscher; Sarah Devriese; Sophie Van Welden; Tom Holvoet; Ramiro Vilchez-Vargas; Marius Vital; Dietmar H Pieper; Julie Vanden Bussche; Lynn Vanhaecke; Tom Van de Wiele; Martine De Vos; Debby Laukens Journal: Appl Environ Microbiol Date: 2017-03-17 Impact factor: 4.792
Authors: E Legaki; M G Roubelakis; G E Theodoropoulos; A Lazaris; A Kollia; G Karamanolis; E Marinos; M Gazouli Journal: Stem Cell Rev Rep Date: 2016-10 Impact factor: 5.739